PROCEPT BioRobotics to Report Second Quarter 2022 Financial Results on August 4, 2022

REDWOOD CITY, Calif., July 14, 2022 (GLOBE NEWSWIRE) — PROCEPT® BioRobotics Corporation (Nasdaq: PRCT), a surgical robotics company focused on advancing patient care by developing transformative solutions in urology, today announced it will report financial results for the second quarter 2022 after market close on Thursday, August 4, 2022. The company’s management will host a corresponding conference call beginning at 1:30 p.m. Pacific Time / 4:30 p.m. Eastern Time. Investors interested in listening to the conference call may do so by following one of the below links: Webcast link for interested listeners: https://edge.media-server.com/mmc/p/87bcav5x [edge.media-server.com] Dial-in registration for sell-side research analysts: https://register.vevent.com/register/BI70e85eb9b03a42e8831726c78237aea4 [register.vevent.com] Live audio of the webcast will be available on the “Investors” section of the company’s website at: https://ir.procept-biorobotics.com. An archived recording will be available on the “Investors” section of the company’s website at: https://ir.procept-biorobotics.com. The webcasts will be available for replay for at least 90 days after the event. About PROCEPT BioRobotics CorporationPROCEPT is a surgical robotics company focused on advancing patient care by developing transformative solutions in urology. PROCEPT develops, manufactures and sells the AquaBeam Robotic System, an advanced, image-guided, surgical robotic system for use in minimally invasive urologic surgery with an initial focus on treating benign prostatic hyperplasia, or BPH. BPH is the most common prostate disease and impacts approximately 40 million men in the United States. PROCEPT designed Aquablation therapy to deliver effective, safe and durable outcomes for males suffering from lower urinary tract symptoms, or LUTS, due to BPH that are independent of prostate size and shape or surgeon experience. PROCEPT has developed a significant and growing body of clinical evidence, which includes nine clinical studies and over 100 peer-reviewed publications, supporting the benefits and clinical advantages of Aquablation therapy. Investor Contact:Gilmartin GroupMatt Bacso, [email protected]